The incidence of immune-mediated hepatitis in patients receiving immunotherapy varies based on the agent and other concomitant medications, though it is not uncommon.
Adverse events observed in sarcoma survivors highlights the increased need for new, safe treatments, as complications may not be seen until years after the completion of therapy.
The US Food and Drug Administration announced a plan to hasten generic drug approvals and thereby increase competition, potentially reducing drug prices altogether.
Cancer Therapy Advisor asked Dr Kumar to discuss his team's investigation into a dexamethasone dosing schedule for reducing the rates of peripheral neuropathy.
Treating physicians should watch for any suspicious signs of cancer after DM is diagnosed.
Cancer Therapy Advisor asked Dr Shaw to discuss ALK- and ROS1-positive NSCLC, including currently available agents and ongoing research to develop additional targeted therapies.
Study results presented at ASCO point to a major advance for immune therapy in advanced CEA-expressing CRC and possibly other CEA-expressing malignancies.
The Supreme Court's ruling in the Amgen v Sandoz case may hasten the arrival of lower-cost biosimilar versions of biologics in the clinic, potentially saving billions of dollars in health care spending.
Vaccines targeting multiple myeloma antigens offer a promising therapeutic approach by helping the immune system to fight off cancer cells.
Don Dizon, MD: In addition to important clinical trial outcomes that evaluated novel strategies across tumor types, there were impressive studies aiming to help our patients live with cancer as well.
In this question-and-answer session, Cancer Therapy Advisor asked Dr Duma about her team's study and minority patient representation in breast cancer studies.
Ulka Vaishampayan, MD, and Neeraj Agarwal, MD, spoke with Cancer Therapy Advisor about treatment recommendations for patients newly diagnosed with metastatic RCC.
The diagnosis of linitis plastica, a subtype of gastric adenocarcinoma with a poor prognosis, can be difficult and uses a multifaceted approach between endoscopic and radiologic studies.
Dual expression of MYC and BCL2 was associated with worse survival among patients with GCB-like DLBCL, though this status was not associated with any outcomes among patients with ABC-like DLBCL.
Researchers are interested in identifying "exceptional responders" to cancer medications to help highlight biomarkers that will identify patients likely to respond to treatment.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Low-fat Diet and Breast Cancer
- The Adverse Effects of Sarcoma Treatment in Cancer Survivors
- Some Patients With Terminal Cancer Receive Unnecessary Aggressive Treatment
- Anti-CD19 CAR-T Cells May Be Safe and Effective in Chronic Lymphocytic Leukemia
- Active Surveillance and Watchful Waiting for Low-risk Prostate Cancer
- Weight in Adolescence May Predict Colorectal Cancer Risk
- Haploidentical Transplantation Effective as Front-line Therapy for Standard-risk ALL
- Ipilimumab Indication Expanded To Include Pediatric Unresectable or Metastatic Melanoma
- Immune-mediated Hepatitis: Challenges in Management
- Phase 1 Study of A Dendritic Cell Vaccine for High-grade Glioma and Glioblastoma